Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Income from Continuing Operations: 2015-2025

Historic Income from Continuing Operations for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$11.2 million.

  • Spyre Therapeutics' Income from Continuing Operations rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
  • Per Spyre Therapeutics' latest filing, its Income from Continuing Operations stood at -$11.2 million for Q3 2025, which was up 69.54% from -$36.7 million recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Income from Continuing Operations peaked at -$11.2 million during Q3 2025, and registered a low of -$217.1 million during Q2 2023.
  • For the 3-year period, Spyre Therapeutics' Income from Continuing Operations averaged around -$58.1 million, with its median value being -$43.9 million (2024).
  • As far as peak fluctuations go, Spyre Therapeutics' Income from Continuing Operations tumbled by 872.45% in 2023, and later surged by 83.80% in 2025.
  • Over the past 5 years, Spyre Therapeutics' Income from Continuing Operations (Quarterly) stood at -$20.4 million in 2021, then climbed by 7.94% to -$18.8 million in 2022, then crashed by 235.67% to -$63.2 million in 2023, then increased by 10.90% to -$56.3 million in 2024, then surged by 83.80% to -$11.2 million in 2025.
  • Its Income from Continuing Operations stands at -$11.2 million for Q3 2025, versus -$36.7 million for Q2 2025 and -$44.8 million for Q1 2025.